Analytic Investors’s ResMed RMD Stock Holding History

Analytic Investors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-47,595	Closed	-$3.42M	–	609
2015 Q1	$3.42M	Buy	+47,595	New	+$3.09M	0.05%	200
2014 Q1	–	Sell	-166,949	Closed	-$7.86M	–	595
2013 Q4	$7.86M	Sell	166,949 -157,285	-49%	-$7.96M	0.13%	149
2013 Q3	$17.1M	Buy	+324,234	New	+$15.7M	0.28%	113

Other funds holding RMD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Analytic Investors's RMD Position: Q2 2015 in Review

Analytic Investors sold out of ResMed (RMD) in Q2 2015, closing a stake of 47,595 shares — an estimated $3.42M sold.

Analytic Investors first reported a position in RMD in Q3 2013 and held it in 3 quarters. The position peaked at $17.1M in Q3 2013. 312 funds tracked by Wall St. Rank hold RMD as of Q2 2015.

Analytic Investors reported no remaining ResMed position as of Q2 2015 after selling out during the quarter.
Analytic Investors sold 47,595 ResMed shares in Q2 2015, an estimated $3.42M.
Analytic Investors first reported a position in ResMed in Q3 2013 and held it in 3 quarters.
Analytic Investors's ResMed position peaked at $17.1M in Q3 2013.
312 funds tracked by Wall St. Rank held ResMed as of Q2 2015.

Based on Analytic Investors's 13F filing for Q2 2015, filed 12 Aug 2015.